Evidence Codex is an educational reference, not medical advice. Many compounds listed are unapproved or have limited human evidence. Read the medical disclaimer.
Evidence CodexResearch, tools and practical guidance
Bioregulators & Organ Support

Epithalon (Epitalon)

← Back to Library
Limited / unverified FDA safety flag Limited / unverified Longevity Circadian
Educational reference only. Read the full disclaimer. The protocols below are not automatically an FDA-approved or clinically verified regimen unless explicitly marked as label-verified or clinical-trial above.

Overview

Route(s): Subcutaneous

Typical vial sizes: 10, 40, 50 mg

Dosing window: Pre-Bed

Receptor / target: TERT

Properties: Not stated

Pre-mixed: No

Unverified protocol notes

Standard Protocol

TimeframeDoseNotes
Days 1-205 mg 1x dailyComplete 20 consecutive days. Administer at bedtime to align with natural pineal melatonin synthesis window. Repeat twice yearly (every 6 months).

Unverified protocol note; not label dosing unless graded otherwise on this page.

Alternative Titration 1: Anecdotal Pulse Protocol (not an Epithalamin study protocol)

TimeframeDoseNotes
Day 110mg 1x daily at bedtimeLimited evidence pulse entry. Do not read Russian/Ukrainian Epithalamin literature as proof that synthetic Epithalon should be used at 10 mg. Treat this as high-uncertainty and not label dosing.
Day 510mg 1x daily at bedtimeLimited evidence pulse entry. Do not read Russian/Ukrainian Epithalamin literature as proof that synthetic Epithalon should be used at 10 mg. Treat this as high-uncertainty and not label dosing.
Day 910mg 1x daily at bedtimeLimited evidence pulse entry. Do not read Russian/Ukrainian Epithalamin literature as proof that synthetic Epithalon should be used at 10 mg. Treat this as high-uncertainty and not label dosing.
Day 1310mg 1x daily at bedtimeLimited evidence pulse entry. Do not read Russian/Ukrainian Epithalamin literature as proof that synthetic Epithalon should be used at 10 mg. Treat this as high-uncertainty and not label dosing.
Day 1710mg 1x daily at bedtimeLimited evidence pulse entry. Do not read Russian/Ukrainian Epithalamin literature as proof that synthetic Epithalon should be used at 10 mg. Treat this as high-uncertainty and not label dosing.
Day 2110mg 1x daily at bedtimeLimited evidence pulse entry. Do not read Russian/Ukrainian Epithalamin literature as proof that synthetic Epithalon should be used at 10 mg. Treat this as high-uncertainty and not label dosing.
Day 2510mg 1x daily at bedtimeLimited evidence pulse entry. Do not read Russian/Ukrainian Epithalamin literature as proof that synthetic Epithalon should be used at 10 mg. Treat this as high-uncertainty and not label dosing.

Limited evidence alternative protocol; the 10 mg Epithalon pulse is not established by Epithalamin studies.

Alternative Titration 2: High-Uncertainty Intensive Protocol

TimeframeDoseNotes
Days 1-1010mg 1x daily at bedtimeHigh-uncertainty limited-evidence entry. The 10 mg/day figure is not established by the classic Epithalamin literature and should not be presented as proven human Epithalon dosing.

Limited evidence alternative protocol; high-dose Epithalon use is not established by Epithalamin studies.

Alternative Titration 3: Longevity Foundation Stack (inspired by pineal/thymic bioregulator literature, not a direct replication)

TimeframeDoseNotes
Days 1-105mg Epithalon SC at bedtime + 10mg Thymalin SC at any time + DSIP 100-500mcg SC at bedtime (30 min before Epithalon)Three-compound concurrent protocol inspired by the pineal/thymic bioregulator literature, but not a direct replication because the classic studies used Epithalamin rather than synthetic Epithalon. DSIP administered first at bedtime to initiate delta wave sleep induction; Epithalon administered 30 minutes later to align with the deepening slow-wave sleep window. Thymalin can be administered at any time of day. Separate injection sites for each compound. Baseline immune panel (CD3/CD4/CD8/NK) and telomere length assessment before initiating.
Days 11-205mg Epithalon SC at bedtime + DSIP 100-500mcg SC at bedtimeThymalin standard course completes at Day 10. Continue Epithalon full 20-day standard course with DSIP support throughout. The sequential completion of Thymalin before Epithalon should not be described as a direct Khavinson-study replication.

Limited evidence alternative protocol; not a direct replication of Epithalamin studies.

Alternative Titration 4: Senolytic Synergy Protocol: Epithalon + FOXO4-DRI (Goal: combine telomerase-mediated prevention of future senescent cell accumulation (Epithalon) with active clearance of existing senescent cells (FOXO4-DRI); most mechanistically complete cellular aging intervention in the database)

TimeframeDoseNotes
Days 1-31.5 mg/kg FOXO4-DRI SC on Days 1, 2, and 3FOXO4-DRI senolytic pulse first. Run FOXO4-DRI standard 3-day clearing course before Epithalon initiation. Rationale: clear existing senescent cell burden before activating telomerase to protect new cell generations: clearing the old first, then protecting the new.
Days 4-235mg Epithalon SC 1x daily at bedtimeBegin Epithalon standard 20-day course immediately following FOXO4-DRI clearing course. The cleared cellular environment allows Epithalon's TERT activation to act on the surviving non-senescent cell population without competition from the high oxidative and inflammatory burden of the pre-existing senescent cell mass.

Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.

Alternative Titration 5: Circadian Restoration and Melatonin Axis Protocol (Goal: prioritize pineal melatonin rhythm normalization and circadian amplitude restoration; indicated for subjects with severe circadian dysfunction, poor sleep architecture, shift work history, or measured low nocturnal melatonin output; complements Endoluten oral cytomedin)

TimeframeDoseNotes
Days 1-52.5mg Epithalon SC at bedtimeHalf-dose titration entry for subjects whose primary goal is circadian restoration rather than maximum TERT activation. Lower dose reduces vivid dream intensity in first days while melatonin rhythm re-establishes. Baseline salivary DLMO melatonin test before initiating.
Days 6-205mg Epithalon SC at bedtimeFull standard dose for remainder of course. Combine with Endoluten 2 capsules before dinner on Days 1-30 for comprehensive pineal cytomedin (Endoluten) + defined synthetic peptide (Epithalon) coverage of the pineal aging axis simultaneously. Salivary melatonin DLMO retest at Day 30.

Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.

Protocol logic check

Protocol context: Bioregulator protocols are often cycle-based because the claim is organ-system signaling rather than acute symptom control. The logic should be organ-specific labs, medical context, and humility about older or vendor-derived evidence. Entry context: target (TERT); route Subcutaneous; timing Pre-Bed. Limited-evidence dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Do not treat Epithalamin studies as direct Epithalon dosing proof. Epithalamin is a pineal extract/bioregulator; Epithalon/Epitalon is the synthetic AEDG tetrapeptide. The popular 10 mg/day claim is not established by the classic Russian/Ukrainian Epithalamin literature, so the protocol notes flag high-dose entries as limited-evidence and high-uncertainty.

Independent evidence

Independent safety notes: FDA lists epitalon among withdrawn nominated bulk substances with insufficient route-specific safety information. Major dosing caveat: much of the Russian/Ukrainian human pineal-peptide literature used Epithalamin, a pineal extract/bioregulator, not synthetic Epithalon/Epitalon. Do not convert those papers into a 10 mg/day Epithalon rule.

Regulatory status: unapproved or compounded peptide with FDA safety risk flag

Storage

No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.

Contraindications (limited evidence)

  • Active malignancy with rapidly proliferating tumor cells: telomerase activation is the primary mechanism of Epithalon; malignant cells already exploit telomerase (TERT) re-expression as a core immortalization strategy; exogenous TERT stimulation in the context of active cancer could theoretically accelerate tumor cell telomere maintenance and proliferative capacity; use in subjects with known active malignancy requires oncological evaluation. Limited / unverified
  • Known TERT-expressing malignancy (most carcinomas, lymphomas, certain sarcomas): same mechanism as above; the subset of cancers most reliant on TERT for immortality represent the highest-risk context for Epithalon use. Limited / unverified
  • Known hypersensitivity to Epithalon, epithalamin-derived peptides, or formulation excipients. Limited / unverified
  • Pregnancy: the epigenetic and telomeric effects of TERT activation during fetal development are not characterized; pineal gland modulation during organogenesis is not established as safe. Limited / unverified
  • Breastfeeding: no safety data. Limited / unverified
  • Concurrent use of telomerase inhibitor investigational agents (in oncology trials): Epithalon's TERT activation directly opposes the mechanism of experimental telomerase inhibitor anticancer therapies. Limited / unverified
  • Pre-existing conditions of telomere lengthening dysregulation (dyskeratosis congenita variants with TERT gain-of-function): in the rare context of existing TERT hyperactivation pathology, additional TERT stimulation is inadvisable. Limited / unverified

Side effects (limited evidence)

  • Vivid dreams and altered dream intensity: the most consistently reported subjective adverse effect; Epithalon's restoration of pineal melatonin secretion and improvement in slow-wave sleep architecture produces dramatically more vivid, narrative, and emotionally rich dreaming; typically experienced as a positive effect but can be disorienting in subjects with prior dream suppression (common with sleep deprivation or alcohol use). Limited / unverified
  • Altered sleep architecture: the first 1-5 days of a new Epithalon cycle may produce transient sleep architecture changes as the pineal melatonin rhythm is re-establishing; subjects may experience unusually deep sleep, difficulty waking at normal times, or altered REM/NREM proportions. Limited / unverified
  • Mild transient fatigue: reported in a minority of subjects in the first days of a cycle; likely related to the acute melatonin rhythm normalization. Limited / unverified
  • Injection site mild reaction: standard subcutaneous peptide injection response; minimal. Limited / unverified
  • Transient mood changes: a small subset of subjects reports mild mood elevation or transient emotional sensitivity during the first week; related to melatonin normalization and its effects on serotonin synthesis pathways (melatonin is downstream of serotonin in pinealocyte biosynthesis). Limited / unverified
  • No endocrine disruption beyond pineal normalization: Epithalon does not affect the HPA axis, sex hormones, thyroid, or growth hormone axis directly; all secondary hormonal effects are downstream of the pineal melatonin restoration. Limited / unverified
  • No documented toxicity at standard doses in the 40+ year Russian clinical use history: the safety profile of Epithalon across decades of Russian and Ukrainian clinical application is exceptionally clean; no serious adverse events have been documented in the published Khavinson literature at standard protocol doses. Limited / unverified
  • Theoretical cancer promotion risk (not documented in clinical data): the TERT activation mechanism raises the theoretical concern above; however, in the 40+ year human use history including elderly subjects (who have the highest background cancer incidence), no increase in cancer rates has been documented: and the published data shows reduced cancer incidence; this remains a mechanistic theoretical concern not supported by the available observational data. Limited / unverified

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

VilonThymalinDSIP (Delta Sleep-Inducing Peptide)FOXO4-DRISelank

Reported contraindicated combinations:

None listed.

Sources